Disclaimer: This guide is only for patients who have been prescribed or due to start Lutetium (177Lu) oxodotreotide (Lutathera® ) a radioligand therapy (RLT) in the UK. It is not intended to replace the advice given to you by your clinical team. You should always speak with a member of your team about any questions you may have. This guide has been developed by Novartis UK and includes links to external materials, such as those developed by the Medicines and Healthcare products Regulatory Agency (MHRA).

Reporting of side effects: If you get any side effects, talk to your doctor, pharmacist or nurse. This includes any possible side effects not listed in the package leaflet. You can also report side effects directly via theb Yellow Card Scheme at https://yellowcard.mhra.gov.uk/